All News

WhyNotTheBest.org maintained by The Commonwealth Fund is a free resource for healthcare professionals interested in tracking performance on various measures of healthcare quality.

Congressional candidates may be still be talking about the Affordable Care Act, but a majority of the uninsured are still unaware of main components of the law, according to a poll from the Kaiser Family Foundation.

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

Industry experts discussed the big issues facing accountable care organizations (ACO) at the Brookings Institute's event, The State of Accountable Care: Evidence to Date and Next Steps, held Monday in Washington, DC.

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

As accountable care organizations, or ACOs, proliferate across the United States, a question arises for both veteran healthcare leaders and consumers: is the ACO something new, or just a relabeling of managed care vehicles created during the last wave of healthcare reform? A well-run ACO offers something better than the managed care of prior years, according to presenters at the gathering of the ACO and Emerging Healthcare Coalition, which took place October 16-17, 2014, in Miami, Florida.

Providers and insurers across the country are partnering to launch narrow-network plans even as controversy continues over whether these plans offer adequate provider access for consumers.

Attendees at the ACO and Emerging Healthcare Delivery Coalition meeting held October 16-17, 2014, in Miami, Fla., gained insights to help physicians and accountable care organizations achieve the "Triple Aim" of better population health, greater patient satisfaction, and lower costs. This initiative of The American Journal of Managed Care has now attracted more than 120 members.

The Office of the National Coordinator for Health Information Technology unveiled a draft for its 10-year plan for healthcare interoperability at a joint meeting on October 15.

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.

A new initiative from the Robert Wood Johnson Foundation will explore how health information and data can be used to improve health in the community.

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.

Brincidofovir is being developed by the company against several different viruses, including smallpox and Ebola.

Myriad Genetics, Inc., announced today that the Medicare Administrative Contractor (MAC) that has jurisdiction over most molecular diagnostic tests has issued its draft notice on how Medicare will provide reimbursement for Prolaris, a test that Myriad has developed to guide treatment decisions in prostate cancer.

Despite continued Republican opposition to the Affordable Care Act, sentiment is shifting from repeal to replace. Still, the fact that open enrollment on HealthCare.gov begins after the midterm elections does not seem like a coincidence to the GOP.

While the current approved immuno-oncolgy drugs have been approved for melanoma, Roche has also been evaluating their new molecule in triple-negative breast cancer. The results will be presented at the San Antonio Breast Cancer Symposium.

A majority of Americans covered by the Affordable Care Act are expecting to change plans for 2015, which may be a smart move, according to industry experts. People who simply re-enroll may not realize they are no longer among the lowest costing plans, which will affect how much their subsidies pay for.

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.

Legal reforms that enact stronger protections against malpractice claims do not necessarily reduce defensive care, according to a new study by the RAND Corporation published in the New England Journal of Medicine.

Massachusetts health officials over-billed Medicaid for almost $106 million by filing claims from as far back as 1988 as current expenses, according to an HHS inspector general's report.

The strict rules of the Meaningful Use (MU) program are preventing physicians from participating, according to the American Medical Association, which is calling for more flexibility and some relief from penalties.

A blog published by The Commonwealth Fund points to digital technology glitches being responsible for slower policy adoption by several state exchanges. But states are fixing their technology glitches and also setting examples for other states to follow, say the authors.

After Roche saw 2 product rejects a few weeks back from NICE, based on a value argument, Celgene is in a similar boat with it's multiple myeloma drug pomalidomide.